The US Federal Trade Commission (FTC) announced Friday it sued three prescription drug benefit managing companies, alleging they inflated insulin drug prices and boosted profits at the expense of vulnerable patients. The regulator claimed that the companies engaged in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs, impaired patients’ access to lower list price products, and shifted the cost of high insulin list ...